Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide SAN ANTONIO, Texas – September 17, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung […]
BIAF continues to be listed and traded on Nasdaq SAN ANTONIO, Texas – September 9, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has received written notice from The Nasdaq Stock Market LLC stating that […]
SAN ANTONIO, Texas – September 3, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings during the H.C. Wainwright 28th Annual […]
More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance Noninvasive CyPath® Lung has the potential to complement imaging in monitoring for lung cancer recurrence and new cancers SAN ANTONIO, Texas – September 1, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive […]
SAN ANTONIO, Texas – August 20, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market […]
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity’s commercial reach through AvMEDICAL’s existing sales team Service-Disabled Veteran-Owned AvMEDICAL provides access to established government procurement channels SAN ANTONIO, Texas – August 18, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology […]